These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32140747)

  • 1. Crystal structures of human NSDHL and development of its novel inhibitor with the potential to suppress EGFR activity.
    Kim DG; Cho S; Lee KY; Cheon SH; Yoon HJ; Lee JY; Kim D; Shin KS; Koh CH; Koo JS; Choi Y; Lee HH; Oh YK; Jeong YS; Chung SJ; Baek M; Jung KY; Lim HJ; Kim HS; Park SJ; Lee JY; Lee SJ; Lee BJ
    Cell Mol Life Sci; 2021 Jan; 78(1):207-225. PubMed ID: 32140747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation.
    Sukhanova A; Gorin A; Serebriiskii IG; Gabitova L; Zheng H; Restifo D; Egleston BL; Cunningham D; Bagnyukova T; Liu H; Nikonova A; Adams GP; Zhou Y; Yang DH; Mehra R; Burtness B; Cai KQ; Klein-Szanto A; Kratz LE; Kelley RI; Weiner LM; Herman GE; Golemis EA; Astsaturov I
    Cancer Discov; 2013 Jan; 3(1):96-111. PubMed ID: 23125191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAD(P)-dependent steroid dehydrogenase-like is involved in breast cancer cell growth and metastasis.
    Yoon SH; Kim HS; Kim RN; Jung SY; Hong BS; Kang EJ; Lee HB; Moon HG; Noh DY; Han W
    BMC Cancer; 2020 May; 20(1):375. PubMed ID: 32366230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies.
    Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K
    Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
    Yang X; Hou Z; Wang D; Mou Y; Guo C
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
    Wood ER; Truesdale AT; McDonald OB; Yuan D; Hassell A; Dickerson SH; Ellis B; Pennisi C; Horne E; Lackey K; Alligood KJ; Rusnak DW; Gilmer TM; Shewchuk L
    Cancer Res; 2004 Sep; 64(18):6652-9. PubMed ID: 15374980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR.
    Gabitova L; Restifo D; Gorin A; Manocha K; Handorf E; Yang DH; Cai KQ; Klein-Szanto AJ; Cunningham D; Kratz LE; Herman GE; Golemis EA; Astsaturov I
    Cell Rep; 2015 Sep; 12(11):1927-38. PubMed ID: 26344763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
    Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
    Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rv1106c from Mycobacterium tuberculosis is a 3beta-hydroxysteroid dehydrogenase.
    Yang X; Dubnau E; Smith I; Sampson NS
    Biochemistry; 2007 Aug; 46(31):9058-67. PubMed ID: 17630785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAD(P)-dependent steroid dehydrogenase-like protein and neutral cholesterol ester hydrolase 1 serve as novel markers for early detection of gastric cancer identified using quantitative proteomics.
    Xiao Y; Xie J; Liu L; Huang W; Han Q; Qin J; Liu S; Jiang Z
    J Clin Lab Anal; 2021 Feb; 35(2):e23652. PubMed ID: 33219617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developmental expression pattern of the cholesterogenic enzyme NSDHL and negative selection of NSDHL-deficient cells in the heterozygous Bpa(1H)/+ mouse.
    Cunningham D; Spychala K; McLarren KW; Garza LA; Boerkoel CF; Herman GE
    Mol Genet Metab; 2009 Dec; 98(4):356-66. PubMed ID: 19631568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSDHL promotes triple-negative breast cancer metastasis through the TGFβ signaling pathway and cholesterol biosynthesis.
    Chen M; Zhao Y; Yang X; Zhao Y; Liu Q; Liu Y; Hou Y; Sun H; Jin W
    Breast Cancer Res Treat; 2021 Jun; 187(2):349-362. PubMed ID: 33864166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FR171456 is a specific inhibitor of mammalian NSDHL and yeast Erg26p.
    Helliwell SB; Karkare S; Bergdoll M; Rahier A; Leighton-Davis JR; Fioretto C; Aust T; Filipuzzi I; Frederiksen M; Gounarides J; Hoepfner D; Hofmann A; Imbert PE; Jeker R; Knochenmuss R; Krastel P; Margerit A; Memmert K; Miault CV; Rao Movva N; Muller A; Naegeli HU; Oberer L; Prindle V; Riedl R; Schuierer S; Sexton JA; Tao J; Wagner T; Yin H; Zhang J; Roggo S; Reinker S; Parker CN
    Nat Commun; 2015 Oct; 6():8613. PubMed ID: 26456460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic and thermodynamic insights into interaction of erlotinib with epidermal growth factor receptor: Surface plasmon resonance and molecular docking approaches.
    Mohammadzadeh-Asl S; Aghanejad A; Yekta R; de la Guardia M; Ezzati Nazhad Dolatabadi J; Keshtkar A
    Int J Biol Macromol; 2020 Nov; 163():954-958. PubMed ID: 32653374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
    Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
    Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profile of NSDHL in human peripheral tissues.
    Morimoto M; Souich Cd; Trinh J; McLarren KW; Boerkoel CF; Hendson G
    J Mol Histol; 2012 Feb; 43(1):95-106. PubMed ID: 22113624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation.
    Li M; Yang J; Zhang L; Tu S; Zhou X; Tan Z; Zhou W; He Y; Li Y
    J Exp Clin Cancer Res; 2019 May; 38(1):211. PubMed ID: 31118055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of mammalian NAD(P)H steroid dehydrogenase-like protein on lipid droplets.
    Ohashi M; Mizushima N; Kabeya Y; Yoshimori T
    J Biol Chem; 2003 Sep; 278(38):36819-29. PubMed ID: 12837764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening.
    Schuster D; Kowalik D; Kirchmair J; Laggner C; Markt P; Aebischer-Gumy C; Ströhle F; Möller G; Wolber G; Wilckens T; Langer T; Odermatt A; Adamski J
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):148-61. PubMed ID: 21300150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.